Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets

Area of Science:

• Hepatology
• Immunology
• Autoimmunity

Background:

• Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease targeting intrahepatic bile ducts.
• PBC presents diverse subtypes: AMA-positive, AMA-negative, and overlap syndromes (e.g., AIH-PBC).
• Distinct autoantibody profiles characterize these subtypes, crucial for diagnosis and understanding pathogenesis.

Purpose of the Study:

• To provide a comprehensive review of autoantibodies in PBC.
• To discuss the diagnostic, prognostic, and pathogenic roles of autoantibodies.
• To explore emerging autoantibodies and their potential in personalized medicine.

Main Methods:

• Literature review of classical and emerging autoantibodies in PBC.
• Analysis of diagnostic significance across PBC subtypes.
• Discussion of pathogenic implications and therapeutic monitoring potential.

Main Results:

• Key autoantibodies include AMA-M2, anti-gp210, anti-sp100, anti-KLHL12, and anti-RPL30.
• Autoantibodies are vital for diagnosing PBC subtypes and overlap syndromes.
• Emerging evidence suggests bile acid-induced neoantigens may drive AMA production.

Conclusions:

• Autoantibody profiling is essential for PBC diagnosis, prognosis, and patient stratification.
• Advanced autoantibody analysis may enable personalized medicine approaches for PBC.
• Further research into autoantibody roles can improve patient outcomes in PBC.